NantKwest Inc. (NASDAQ:NK) and SELLAS Life Sciences Group Inc. (NASDAQ:SLS) are two firms in the Biotechnology that compete against each other. Below is a comparison of their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NantKwest Inc.	N/A	2086.57	96.23M	-0.65	0.00
SELLAS Life Sciences Group Inc.	N/A	0.00	41.25M	-4.96	0.00

In table 1 we can see NantKwest Inc. and SELLAS Life Sciences Group Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 has NantKwest Inc. and SELLAS Life Sciences Group Inc.’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
NantKwest Inc.	0.00%	-54.2%	-46.3%
SELLAS Life Sciences Group Inc.	0.00%	-625.6%	-76.1%

Volatility and Risk

A 2.72 beta means NantKwest Inc.’s volatility is 172.00% more than Standard & Poor’s 500’s volatility. Competitively, SELLAS Life Sciences Group Inc. is 70.00% more volatile than Standard & Poor’s 500, because of the 1.7 beta.

Liquidity

The current Quick Ratio of NantKwest Inc. is 3.3 while its Current Ratio is 3.3. Meanwhile, SELLAS Life Sciences Group Inc. has a Current Ratio of 1.5 while its Quick Ratio is 1.5. NantKwest Inc. is better positioned to pay off its short-term and long-term debts than SELLAS Life Sciences Group Inc.

Analyst Ratings

The next table highlights the delivered recommendations and ratings for NantKwest Inc. and SELLAS Life Sciences Group Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
NantKwest Inc.	0	1	0	2.00
SELLAS Life Sciences Group Inc.	0	0	1	3.00

NantKwest Inc.’s upside potential is 61.29% at a $2 average target price. Competitively the average target price of SELLAS Life Sciences Group Inc. is $4.5, which is potential 354.55% upside. The results provided earlier shows that SELLAS Life Sciences Group Inc. appears more favorable than NantKwest Inc., based on analyst view.

Institutional and Insider Ownership

NantKwest Inc. and SELLAS Life Sciences Group Inc. has shares held by institutional investors as follows: 11.5% and 31.1%. Insiders held roughly 65.43% of NantKwest Inc.’s shares. Competitively, 1.9% are SELLAS Life Sciences Group Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
NantKwest Inc.	0.85%	10.19%	-31.61%	-61.11%	-72.95%	2.59%
SELLAS Life Sciences Group Inc.	-1.41%	-4.11%	-17.65%	33.6%	-72%	13.82%

For the past year NantKwest Inc. has weaker performance than SELLAS Life Sciences Group Inc.

Summary

NantKwest Inc. beats on 5 of the 9 factors SELLAS Life Sciences Group Inc.

NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the companyÂ’s proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

SELLAS Life Sciences Group, Inc., a development-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S, a cancer immunotherapeutic agent for the treatment of hematologic cancers and solid tumor indications, including acute myeloid leukemia, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, immune combo, and chronic myelogenous leukemia. It also develops NEUVAX, which is in Phase II clinical trial for the treatment of breast cancer; and Anagrelide controlled release, which has completed various clinical trials for the treatment of thrombocythemia. The company has collaboration and license agreements with Memorial Sloan Kettering Cancer Center, Advaxis Immunotherapies, Merck & Co., Inc., National Cancer Institute, and the University of Texas M.D. Anderson Cancer Center. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.